The FDA granted orphan-drug status to Patrys' lead cancer candidate PAT-SM6. Patrys said the drug binds to more than 90% of tumors they have screened, regardless of the type and stage of cancer, or patients' gender and age. PAT-SM6 received a similar designation in Europe.
FDA awards orphan designation to Patrys' cancer candidate
SmartBrief Job Listings for Health Care
|Chief Financial Officer||
B. E. Smith
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|